{"filing":{"accession_number":"0001493152-26-030341","cik":"0001541157","ticker":"AKTX","company_name":"Akari Therapeutics Plc","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226030341/form8-k.htm"},"events":[{"id":14356,"run_id":12781,"accession_number":"0001493152-26-030341","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses a private placement of 1,470,588 unregistered ADSs (or prefunded warrants) representing 80,000 ordinary shares per ADS, together with Series H, I, and J warrants. This is a classic dilutive equity issuance to raise capital. The amendment consolidates the second and third closing dates into a single combined closing on June 26, 2026, with the remaining 980,395 ADSs delivered on that date. The unregistered nature and warrant components are hallmarks of a dilutive capital raise at a small-cap biotech company.","company_name":"Akari Therapeutics Plc","ticker":"AKTX","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11751,"accession_number":"0001493152-26-030341","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a private placement of 1,470,588 unregistered ADSs (or prefunded warrants) representing 80,000 ordinary shares per ADS, together with Series H, I, and J warrants. This is a classic dilutive equity issuance to raise capital. The amendment consolidates the second and third closing dates into a single combined closing on June 26, 2026, with the remaining 980,395 ADSs delivered on that date. The unregistered nature and warrant components are hallmarks of a dilutive capital raise at a small-cap biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T21:16:51.025932+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11751,"accession_number":"0001493152-26-030341","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a private placement of 1,470,588 unregistered ADSs (or prefunded warrants) representing 80,000 ordinary shares per ADS, together with Series H, I, and J warrants. This is a classic dilutive equity issuance to raise capital. The amendment consolidates the second and third closing dates into a single combined closing on June 26, 2026, with the remaining 980,395 ADSs delivered on that date. The unregistered nature and warrant components are hallmarks of a dilutive capital raise at a small-cap biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T21:16:51.025932+00:00","company_name":"Akari Therapeutics Plc","ticker":"AKTX","filing_date":"2026-06-26"}]}